Inhaled Nitric Oxide Treatment for Aneurysmal SAH Patients With Intractable Cerebral Vasospasm

NACompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

July 28, 2019

Study Completion Date

March 20, 2020

Conditions
SAHInhaled Nitric OxideCerebral IschemiaVasospasm
Interventions
DRUG

Inhaled nitric oxide

Each increase of iNO dose is followed by a 10-minute monitoring period and a DSA examination. After reaching the highest effective dose of iNO or the maximum of 40 ppm another DSA is performed. iNO is going to be continued until normalisation of CVS or for a maximum period of 5 days. During iNO treatment a DSA will be performed every 24 hours, followed by a decrease of iNO to the next-lower level. If tapering the iNO concentration is associated with increasing vasospasm, iNO is going to be increased again to the last effective dosage. For cessation of iNO administration, dosage will be tapered every 30 minutes using the same dosage steps as for initiation of iNO treatment. If the duration of iNO treatment will be more than 32 hours, tapering intervals are prolonged to 4 hours. Cessation of iNO will be followed by a DSA.

Trial Locations (1)

3010

Department of Neurosurgery, University Hospital Bern, Bern

All Listed Sponsors
lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT04988932 - Inhaled Nitric Oxide Treatment for Aneurysmal SAH Patients With Intractable Cerebral Vasospasm | Biotech Hunter | Biotech Hunter